Advances in synthesis of novel annulated azecines and their unique pharmacological properties.
Anticancer agents
Antipsychotic agents
Aza-Claisen rearrangement
Benzazecines
Dopaminergic receptors ligands
Ring-closing metathesis reactions
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
12
08
2024
revised:
26
09
2024
accepted:
05
10
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
22
10
2024
Statut:
aheadofprint
Résumé
Annulated azecines, mostly partially saturated benzo[d]azecine and dibenzo[c,g]azecine fusion isomers, constitute a unique class of alkaloids and nature-inspired azaheterocyclic compounds with interesting reactivity, physicochemical and biological properties. Due to difficulties associated with the synthesis of the benzazecine (or bioisosteric) scaffold they are not the focus of organic and medicinal chemists' consideration, whereas it is worth noting the range of their pharmacological activities and their potential application in medicinal chemistry. Herein, we reviewed the synthetic methodologies of arene-fused azecine derivatives known up to date and reported about the progress in disclosing their potential in drug discovery. Indeed, their conformational restriction or liberation drives their selectivity towards diverse biological targets, making them versatile scaffolds for developing drugs, including antipsychotic and anticancer drugs, but also small molecules with potential for anti-neurodegenerative treatments, as the recent literature shows.
Identifiants
pubmed: 39437575
pii: S0223-5234(24)00828-6
doi: 10.1016/j.ejmech.2024.116947
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
116947Informations de copyright
Copyright © 2024. Published by Elsevier Masson SAS.
Déclaration de conflit d'intérêts
Declaration of competing interest On behalf of all the co-authors, I declare that the authors of the manuscript entitled “Advances in synthesis of novel benzazecines and their unique pharmacological properties” have no competing interests to declare.